CLU and ovarian cancer: In the current study, we firstly demonstrated that OGX-011, a second-generation antisense oligodeoxynuclotide targeting the translation initiation site of human CLU gene exon II with a long tissue half-life, can modulate sensitivity to TX in an acquired TX-resistant ovarian cancer cell line.